15th Jan 2016 08:33
LONDON (Alliance News) - Premaitha Health PLC on Friday welcomed the recommendation made by the UK National Screening Committee to routinely-offer non-invasive pre-natal testing on the NHS to high-risk pregnant women as part of a standard fetal anomaly screening programme.
Premaitha is behind the IONA non-invasive pre-natal test.
"Today's NSC recommendation is a key milestone for prenatal testing in the UK. This is the first time that NIPT will be routinely available to high risk pregnant women on the NHS and sets a precedent that we expect other countries to follow in the near future," said Premaitha Chief Executive Stephen Little.
This is an important step towards NIPT becoming available to all pregnant women, not just those at high risk. Premaitha is uniquely positioned to bring the benefits of NIPT to the NHS," Little added.
Shares in Premaitha were up 6.5% to 16.5 pence early Friday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Premaitha Health